U.S. stock markets hit record highs after September's inflation data showed a softer-than-expected 3% annual rate, boosting investor confidence in potential Federal Reserve interest rate cuts. Major indices like S&P 500 and Dow Jones reached new peaks, with technology stocks leading the rally.

Inhibrx Biosciences announced positive Phase 2 trial results for ozekibart in treating chondrosarcoma, demonstrating significant progression-free survival improvement and becoming the first experimental therapy to show such benefit in this cancer type.

JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.

Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.

Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.

Historically, consumer sentiment doesn't usually pick up while the business outlook is gloomy, except coming out of recessions.

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Inhibrx The Trade: Inhibrx, Inc. (NASDAQ: INBX) Sharon Rose Shabet acquired a total of 511,627 shares an average price ...

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment. Tivic Health Systems, Inc. (NASDAQ: TIVC) gained 73.4% to $3.37 after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on AmerisourceBergen’s third-party marketplace. iCoreConnect Inc. (NASDAQ: ICCT) shares gained 70.4% to $2.7089 after dipping 20% on Monday. LifeVantage Corporation (NASDAQ: LFVN) gained 28.6% to $6.62 after the company posted fourth-quarter results and declared a special one-time cash dividend of $0.40 per share of common stock. EBET, Inc. (NASDAQ: EBET) rose 28% to $0.0501. Akso Health Group (NASDAQ: AHG) surged 25.6% to $0.6661. Big Lots, Inc. (NYSE: BIG) gained 23.3% to $7.78 following better-than-expected quarterly results. Globalstar, Inc. (NYSE: GSAT) rose 21% to $1.2850 after the company announced it appointed Dr. Paul Jacobs as CEO and announced an agreement to license XCOM Labs technology. UP Fintech Holding Limited (NASDAQ: TIGR) gained 20.3% to $4.3450 following strong quarterly results. Shineco, Inc. (NASDAQ: SISI) shares rose 20% to $0.1732 after declining over 3% on Monday. Caravelle International Group (NASDAQ: CACO) shares climbed 19.2% to $0.6676 after falling 11% on Monday. PDD Holdings Inc. (NASDAQ: PDD) rose 17.5% to ...